2. Search Result
Search Result
Results for "

KIF5B

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-133551
    WF-47-JS03

    		RET Cancer
    WF-47-JS03 is a potent and selective RET kinase inhibitor with IC50s of 1.7 nM and 5.3 nM for KIF5B-RET transfected Ba/F3 cells and CCDC6-RET transfected LC-2/ad lung cancer cells, respectively. WF-47-JS03 demonstrates >500-fold selectivity against kinase insert domain receptor (KDR). Effective brain penetration .
    WF-47-JS03
  • HY-RS07290
    KIF5B Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KIF5B Human Pre-designed siRNA Set A contains three designed siRNAs for KIF5B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KIF5B Human Pre-designed siRNA Set A
    KIF5B Human Pre-designed siRNA Set A
  • HY-RS24765
    Kif5b Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Kif5b Rat Pre-designed siRNA Set A contains three designed siRNAs for Kif5b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Kif5b Rat Pre-designed siRNA Set A
    Kif5b Rat Pre-designed siRNA Set A
  • HY-RS18287
    Kif5b Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Kif5b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kif5b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Kif5b Mouse Pre-designed siRNA Set A
    Kif5b Mouse Pre-designed siRNA Set A
  • HY-170852
    QZ2135

    		PROTACs RET Cancer
    QZ2135 (compound 20) is a RET-targeted PROTAC degrader with in vivo antitumor properties in a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The degradation activities of QZ2135 targeting KIF5B-RET have DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C), respectively. QZ2135 is composed of a target protein ligand (red part) RET ligand-3 (HY-170853), an E3 ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC Linker (black part) 7-Iodohept-1-yne (HY-W587352), in which the target protein ligand + linker form a conjugate RET Ligand-Linker Conjugate-1 (HY-170854) .
    QZ2135
  • HY-146710
    RET-IN-16

    		RET Cancer
    RET-IN-16 is a potent and selective RET inhibitor with IC50s of 3.98 nM, 8.42 nM, 15.05 nM, 7.86 nM, 5.43 nM and 8.86 nM for RET(WT), RET(M918T), RET(V804L), RET(V804M), RET-CCDC6 and RET-KIF5B, respectively. RET-IN-16 has anticancer effects .
    RET-IN-16
  • HY-170855A
    YW-N-7 TFA

    		PROTACs RET Cancer
    YW-N-7 (TFA) is a PROTAC that targets both the inhibition and degradation of RET kinase, with a DC50 of 88 nM. YW-N-7 (TFA) exhibits antitumor activity in a KIF5B-RET-driven xenograft mouse tumor model and can be used in the area of cancer (Structure: red part represents the target protein ligand: HY-170856; blue part represents the E3 ligase ligand: HY-1708557; black part represents the linker; E3 ligase ligand + linker: HY-170858) .
    YW-N-7 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: